Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA grants fast track status to Prima BioMed's CVac program

May 12, 2014

Cellmid selects lead anti-MK antibody in oncology

May 12, 2014

PSMA MAb [177Lu]J-591 tested for treatment of metastatic solid tumors

May 12, 2014

New anticancer agents patented by Chinese scientists

May 9, 2014

Mologen files clinical trial applications for phase III trial of anticancer immunostimulant

May 8, 2014

FDA accepts MK-3475 BLA for review in advanced melanoma

May 8, 2014

IDH1 gene mutation-specific vaccine developed for treatment of patients with glioma

May 8, 2014

Advaxis' immunotherapy product to enter clinic for pediatric bone cancer

May 6, 2014

FDA grants orphan drug designation to OncoMed's demcizumab for pancreatic cancer

May 5, 2014

ADXS-HPV receives FDA orphan drug designation for invasive cervical cancer

May 5, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...